Bowhead Specialty Holdings Inc. Reports Fourth Quarter 2024 Results
Bowhead Specialty Holdings (NYSE: BOW) announced its Q4 2024 financial results. Gross written premiums rose 26.3% to $184.8 million. Net income was $13.6 million, or $0.41 per diluted share, while adjusted net income was $14.1 million, or $0.42 per diluted share. The return on equity was 14.8%, and adjusted return on equity was 15.3%. Book value per share stood at $11.34, and diluted book value per share was $11.03.
For the full year 2024, gross written premiums increased 37.0% to $695.7 million. Net income reached $38.2 million, or $1.29 per diluted share, with adjusted net income at $42.7 million, or $1.44 per diluted share. The return on equity was 13.6%, and adjusted return on equity was 15.2%.
The Casualty division led growth with a 56% increase in premiums. The Healthcare Liability and Professional Liability divisions also saw double-digit growth. Bowhead launched Baleen, a tech-enabled underwriting operation, which generated $1.2 million in gross written premiums in Q4, a 175% sequential growth.
The loss ratio for 2024 was 64.4%, up from 63.0% in 2023. The expense ratio decreased to 31.4% for the year. Net investment income surged 107.1% to $40.1 million, with a book yield of 4.6% and a new money rate of 4.9%.
Bowhead Specialty Holdings (NYSE: BOW) ha annunciato i risultati finanziari per il quarto trimestre del 2024. I premi lordi scritti sono aumentati del 26,3% a 184,8 milioni di dollari. L'utile netto è stato di 13,6 milioni di dollari, ovvero 0,41 dollari per azione diluita, mentre l'utile netto rettificato è stato di 14,1 milioni di dollari, o 0,42 dollari per azione diluita. Il ritorno sul capitale è stato del 14,8%, e il ritorno sul capitale rettificato è stato del 15,3%. Il valore contabile per azione si è attestato a 11,34 dollari, e il valore contabile diluito per azione era di 11,03 dollari.
Per l'intero anno 2024, i premi lordi scritti sono aumentati del 37,0% a 695,7 milioni di dollari. L'utile netto ha raggiunto i 38,2 milioni di dollari, ovvero 1,29 dollari per azione diluita, con un utile netto rettificato di 42,7 milioni di dollari, o 1,44 dollari per azione diluita. Il ritorno sul capitale è stato del 13,6%, e il ritorno sul capitale rettificato è stato del 15,2%.
La divisione Casualty ha guidato la crescita con un aumento del 56% dei premi. Anche le divisioni Healthcare Liability e Professional Liability hanno registrato una crescita a doppia cifra. Bowhead ha lanciato Baleen, un'operazione di underwriting abilitata dalla tecnologia, che ha generato 1,2 milioni di dollari in premi lordi scritti nel quarto trimestre, con una crescita sequenziale del 175%.
Il rapporto di perdita per il 2024 è stato del 64,4%, in aumento rispetto al 63,0% del 2023. Il rapporto di spesa è diminuito al 31,4% per l'anno. Il reddito netto da investimenti è aumentato del 107,1% a 40,1 milioni di dollari, con un rendimento contabile del 4,6% e un tasso di nuovo denaro del 4,9%.
Bowhead Specialty Holdings (NYSE: BOW) anunció sus resultados financieros del cuarto trimestre de 2024. Las primas brutas escritas aumentaron un 26,3% a 184,8 millones de dólares. La utilidad neta fue de 13,6 millones de dólares, o 0,41 dólares por acción diluida, mientras que la utilidad neta ajustada fue de 14,1 millones de dólares, o 0,42 dólares por acción diluida. El retorno sobre el capital fue del 14,8%, y el retorno ajustado sobre el capital fue del 15,3%. El valor contable por acción se situó en 11,34 dólares, y el valor contable diluido por acción fue de 11,03 dólares.
Para el año completo 2024, las primas brutas escritas aumentaron un 37,0% a 695,7 millones de dólares. La utilidad neta alcanzó los 38,2 millones de dólares, o 1,29 dólares por acción diluida, con una utilidad neta ajustada de 42,7 millones de dólares, o 1,44 dólares por acción diluida. El retorno sobre el capital fue del 13,6%, y el retorno ajustado sobre el capital fue del 15,2%.
La división de Casualty lideró el crecimiento con un aumento del 56% en las primas. Las divisiones de Healthcare Liability y Professional Liability también vieron un crecimiento de dos dígitos. Bowhead lanzó Baleen, una operación de suscripción habilitada por tecnología, que generó 1,2 millones de dólares en primas brutas escritas en el cuarto trimestre, un crecimiento secuencial del 175%.
La relación de pérdidas para 2024 fue del 64,4%, un aumento respecto al 63,0% en 2023. La relación de gastos disminuyó al 31,4% para el año. Los ingresos netos por inversiones se dispararon un 107,1% a 40,1 millones de dólares, con un rendimiento contable del 4,6% y una tasa de nuevo dinero del 4,9%.
Bowhead Specialty Holdings (NYSE: BOW)는 2024년 4분기 재무 결과를 발표했습니다. 총 보험료는 26.3% 증가하여 1억 8480만 달러에 달했습니다. 순이익은 1360만 달러, 즉 희석 주당 0.41 달러였으며, 조정된 순이익은 1410만 달러, 즉 희석 주당 0.42 달러였습니다. 자기자본이익률은 14.8%, 조정된 자기자본이익률은 15.3%였습니다. 주당 장부 가치는 11.34 달러, 희석 주당 장부 가치는 11.03 달러로 나타났습니다.
2024년 전체 연도에 대해 총 보험료는 37.0% 증가하여 6억 9570만 달러에 달했습니다. 순이익은 3820만 달러, 즉 희석 주당 1.29 달러에 도달했으며, 조정된 순이익은 4270만 달러, 즉 희석 주당 1.44 달러였습니다. 자기자본이익률은 13.6%, 조정된 자기자본이익률은 15.2%였습니다.
Casualty 부문은 보험료가 56% 증가하여 성장을 이끌었습니다. Healthcare Liability와 Professional Liability 부문도 두 자릿수 성장을 보였습니다. Bowhead는 기술 기반의 인수 운영인 Baleen을 출시하여 4분기 동안 120만 달러의 총 보험료를 생성했으며, 이는 175%의 순차적 성장입니다.
2024년 손실 비율은 64.4%로, 2023년의 63.0%에서 증가했습니다. 경비 비율은 연간 31.4%로 감소했습니다. 순 투자 수익은 107.1% 증가하여 4010만 달러에 달했으며, 장부 수익률은 4.6%, 신규 자금 비율은 4.9%였습니다.
Bowhead Specialty Holdings (NYSE: BOW) a annoncé ses résultats financiers pour le quatrième trimestre 2024. Les primes brutes écrites ont augmenté de 26,3 % pour atteindre 184,8 millions de dollars. Le bénéfice net s'est élevé à 13,6 millions de dollars, soit 0,41 dollar par action diluée, tandis que le bénéfice net ajusté était de 14,1 millions de dollars, soit 0,42 dollar par action diluée. Le retour sur capitaux propres était de 14,8 %, et le retour ajusté sur capitaux propres était de 15,3 %. La valeur comptable par action s'élevait à 11,34 dollars, et la valeur comptable diluée par action était de 11,03 dollars.
Pour l'année entière 2024, les primes brutes écrites ont augmenté de 37,0 % pour atteindre 695,7 millions de dollars. Le bénéfice net a atteint 38,2 millions de dollars, soit 1,29 dollar par action diluée, avec un bénéfice net ajusté de 42,7 millions de dollars, soit 1,44 dollar par action diluée. Le retour sur capitaux propres était de 13,6 %, et le retour ajusté sur capitaux propres était de 15,2 %.
La division Casualty a conduit la croissance avec une augmentation de 56 % des primes. Les divisions Healthcare Liability et Professional Liability ont également connu une croissance à deux chiffres. Bowhead a lancé Baleen, une opération de souscription soutenue par la technologie, qui a généré 1,2 million de dollars en primes brutes écrites au quatrième trimestre, soit une croissance séquentielle de 175 %.
Le ratio de pertes pour 2024 était de 64,4 %, en hausse par rapport à 63,0 % en 2023. Le ratio des dépenses a diminué à 31,4 % pour l'année. Le revenu net d'investissement a bondi de 107,1 % pour atteindre 40,1 millions de dollars, avec un rendement comptable de 4,6 % et un taux de nouveau financement de 4,9 %.
Bowhead Specialty Holdings (NYSE: BOW) hat seine finanziellen Ergebnisse für das vierte Quartal 2024 bekannt gegeben. Die brutto geschriebenen Prämien stiegen um 26,3% auf 184,8 Millionen Dollar. Der Nettogewinn betrug 13,6 Millionen Dollar oder 0,41 Dollar pro verwässerter Aktie, während der bereinigte Nettogewinn 14,1 Millionen Dollar oder 0,42 Dollar pro verwässerter Aktie betrug. Die Eigenkapitalrendite betrug 14,8%, und die bereinigte Eigenkapitalrendite lag bei 15,3%. Der Buchwert pro Aktie betrug 11,34 Dollar, und der verwässerte Buchwert pro Aktie lag bei 11,03 Dollar.
Für das gesamte Jahr 2024 stiegen die brutto geschriebenen Prämien um 37,0% auf 695,7 Millionen Dollar. Der Nettogewinn erreichte 38,2 Millionen Dollar oder 1,29 Dollar pro verwässerter Aktie, während der bereinigte Nettogewinn bei 42,7 Millionen Dollar oder 1,44 Dollar pro verwässerter Aktie lag. Die Eigenkapitalrendite betrug 13,6%, und die bereinigte Eigenkapitalrendite lag bei 15,2%.
Die Sparte Casualty führte das Wachstum mit einem Anstieg der Prämien um 56% an. Auch die Bereiche Healthcare Liability und Professional Liability verzeichneten zweistelliges Wachstum. Bowhead hat Baleen, eine technologiegestützte Underwriting-Operation, ins Leben gerufen, die im vierten Quartal 1,2 Millionen Dollar an brutto geschriebenen Prämien erzielte, was einem sequenziellen Wachstum von 175% entspricht.
Die Schadensquote für 2024 betrug 64,4%, ein Anstieg gegenüber 63,0% im Jahr 2023. Die Aufwandsquote sank auf 31,4% für das Jahr. Der Nettogewinn aus Investitionen stieg um 107,1% auf 40,1 Millionen Dollar, mit einer Buchrendite von 4,6% und einem neuen Geldsatz von 4,9%.
- Gross written premiums up 26.3% in Q4
- Net income of $13.6 million in Q4
- Adjusted net income of $14.1 million in Q4
- Return on equity of 14.8% in Q4
- Gross written premiums up 37.0% for 2024
- Net income of $38.2 million for 2024
- Adjusted net income of $42.7 million for 2024
- Return on equity of 13.6% for 2024
- Casualty division premiums up 56%
- Baleen underwriting operation generated $1.2 million in Q4
- Net investment income up 107.1% for 2024
- Loss ratio increased to 64.4% for 2024
Fourth Quarter 2024 Highlights
-
Gross written premiums increased
26.3% to .$184.8 million -
Net income of
, or$13.6 million per diluted share.$0.41 -
Adjusted net income(2) of
, or$14.1 million per diluted share(2).$0.42 -
Return on equity of
14.8% and adjusted return on equity(2) of15.3% . -
Book value per share
and diluted book value per share of$11.34 .$11.03
Full Year 2024 Highlights
-
Gross written premiums increased
37.0% to .$695.7 million -
Net income of
, or$38.2 million per diluted share.$1.29 -
Adjusted net income(2) of
, or$42.7 million per diluted share(2).$1.44 -
Return on equity of
13.6% and adjusted return on equity(2) of15.2% .
Bowhead Chief Executive Officer, Stephen Sills, commented, “After completing our fourth year of operations, we are once again incredibly proud of what we’ve accomplished. This milestone year as a new public company has been defined by profitable growth, continued innovation, and strong execution across all our underwriting divisions. Premiums grew
Underwriting Results
The
-
Our Casualty division led the growth with a
43.1% increase to ;$105.9 million -
Healthcare Liability increased
8.8% to ; and$31.7 million -
Professional Liability increased
6.5% to .$46.0 million -
Late in the second quarter of 2024, we launched a new division called Baleen Specialty, which focuses on small, hard-to-place risks written
100% on a non-admitted basis. Baleen is a streamlined, tech-enabled low touch “flow” underwriting operation that supplements the “craft” solutions we offer today. In line with our deliberate, measured and limited roll out, Baleen Specialty generated of gross written premiums for the fourth quarter of 2024, a sequential growth of$1.2 million 175% from the previous quarter.
Our loss ratio for the year of
During the quarter, as part of our annual independent actuarial reserve review, we reallocated prior accident year loss reserves by division, primarily from Professional Liability to Casualty, to align more closely with industry loss ratios. The increase in our loss ratio and reallocation of prior accident year reserves are primarily based on inputs from industry data due to Bowhead’s limited loss experience. As of December 31, 2024, incurred but not reported liabilities comprised
Our expense ratio for the fourth quarter of
Investment Results
Net investment income increased
The weighted average effective duration of our investment portfolio, which included cash equivalents, was 2.2 years and had an average rating of “AA” at December 31, 2024.
____________________ |
||
(1) |
|
Comparisons in this release are made to December 31, 2023 financial results unless otherwise noted. |
(2) |
|
Non-GAAP financial measure. See “Reconciliation of Non-GAAP Financial Measures” for a reconciliation of the non-GAAP financial measures to their most directly comparable |
Summary of Operating Results
The following table summarizes the Company’s results of operations for the three and twelve months ended December 31, 2024 and 2023:
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
% Change |
|
|
2024 |
|
|
|
2023 |
|
|
% Change |
||
|
($ in thousands, except percentages and per share data) |
||||||||||||||||||||
Gross written premiums |
$ |
184,769 |
|
|
$ |
146,321 |
|
|
26.3 |
% |
|
$ |
695,717 |
|
|
$ |
507,688 |
|
|
37.0 |
% |
Ceded written premiums |
|
(64,585 |
) |
|
|
(51,376 |
) |
|
25.7 |
% |
|
|
(244,295 |
) |
|
|
(173,016 |
) |
|
41.2 |
% |
Net written premiums |
$ |
120,184 |
|
|
$ |
94,945 |
|
|
26.6 |
% |
|
$ |
451,422 |
|
|
$ |
334,672 |
|
|
34.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Revenues |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net earned premiums |
$ |
106,864 |
|
|
$ |
75,992 |
|
|
40.6 |
% |
|
$ |
385,111 |
|
|
$ |
263,902 |
|
|
45.9 |
% |
Net investment income |
|
12,193 |
|
|
|
6,782 |
|
|
79.8 |
% |
|
|
40,121 |
|
|
|
19,371 |
|
|
107.1 |
% |
Net realized investment losses |
|
— |
|
|
|
— |
|
|
NM |
|
|
|
(16 |
) |
|
|
— |
|
|
NM |
|
Other insurance-related income |
|
274 |
|
|
|
31 |
|
|
783.9 |
% |
|
|
444 |
|
|
|
125 |
|
|
255.2 |
% |
Total revenues |
|
119,331 |
|
|
|
82,805 |
|
|
44.1 |
% |
|
|
425,660 |
|
|
|
283,398 |
|
|
50.2 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Expenses |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net losses and loss adjustment expenses |
|
66,937 |
|
|
|
52,618 |
|
|
27.2 |
% |
|
|
248,099 |
|
|
|
166,282 |
|
|
49.2 |
% |
Net acquisition costs |
|
9,130 |
|
|
|
5,787 |
|
|
57.8 |
% |
|
|
32,397 |
|
|
|
20,935 |
|
|
54.8 |
% |
Operating expenses |
|
23,352 |
|
|
|
18,001 |
|
|
29.7 |
% |
|
|
89,112 |
|
|
|
63,456 |
|
|
40.4 |
% |
Non-operating expenses |
|
622 |
|
|
|
630 |
|
|
(1.3 |
)% |
|
|
2,807 |
|
|
|
630 |
|
|
345.6 |
% |
Warrant expense |
|
792 |
|
|
|
— |
|
|
NM |
|
|
|
1,917 |
|
|
|
— |
|
|
NM |
|
Credit facility interest expenses and fees |
|
248 |
|
|
|
— |
|
|
NM |
|
|
|
725 |
|
|
|
— |
|
|
NM |
|
Foreign exchange losses (gains) |
|
1 |
|
|
|
(41 |
) |
|
(102.4 |
)% |
|
|
68 |
|
|
|
(20 |
) |
|
(440.0 |
)% |
Total expenses |
|
101,082 |
|
|
|
76,995 |
|
|
31.3 |
% |
|
|
375,125 |
|
|
|
251,283 |
|
|
49.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Income before income taxes |
|
18,249 |
|
|
|
5,810 |
|
|
214.1 |
% |
|
|
50,535 |
|
|
|
32,115 |
|
|
57.4 |
% |
Income tax expense |
|
(4,642 |
) |
|
|
(1,027 |
) |
|
352.0 |
% |
|
|
(12,292 |
) |
|
|
(7,068 |
) |
|
73.9 |
% |
Net income |
$ |
13,607 |
|
|
$ |
4,783 |
|
|
184.5 |
% |
|
$ |
38,243 |
|
|
$ |
25,047 |
|
|
52.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Key Operating and Financial Metrics: |
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Adjusted net income(1) |
$ |
14,099 |
|
|
$ |
5,793 |
|
|
143.4 |
% |
|
$ |
42,686 |
|
|
$ |
26,152 |
|
|
63.2 |
% |
Loss ratio |
|
62.6 |
% |
|
|
69.2 |
% |
|
|
|
|
64.4 |
% |
|
|
63.0 |
% |
|
|
||
Expense ratio |
|
30.1 |
% |
|
|
31.3 |
% |
|
|
|
|
31.4 |
% |
|
|
31.9 |
% |
|
|
||
Combined ratio |
|
92.7 |
% |
|
|
100.5 |
% |
|
|
|
|
95.8 |
% |
|
|
94.9 |
% |
|
|
||
Return on equity(2) |
|
14.8 |
% |
|
|
11.0 |
% |
|
|
|
|
13.6 |
% |
|
|
18.2 |
% |
|
|
||
Adjusted return on equity(1)(2) |
|
15.3 |
% |
|
|
13.4 |
% |
|
|
|
|
15.2 |
% |
|
|
19.0 |
% |
|
|
||
Diluted earnings per share |
$ |
0.41 |
|
|
$ |
0.20 |
|
|
|
|
$ |
1.29 |
|
|
$ |
1.04 |
|
|
|
||
Diluted adjusted earnings per share(1) |
$ |
0.42 |
|
|
$ |
0.24 |
|
|
|
|
$ |
1.44 |
|
|
$ |
1.09 |
|
|
|
____________________ |
||
NM - Percentage change is not meaningful. |
||
(1) |
|
Non-GAAP financial measure. See “Reconciliation of Non-GAAP Financial Measures” for a reconciliation of the non-GAAP financial measures to their most directly comparable |
(2) |
|
For the three months ended December 31, 2024 and 2023, net income and adjusted net income are annualized to arrive at return on equity and adjusted return on equity. |
Condensed Consolidated Balance Sheets
|
December 31,
|
|
December 31,
|
||||
|
($ in thousands, except share data) |
||||||
Assets |
|
|
|
||||
Investments |
|
|
|
||||
Fixed maturity securities, available for sale, at fair value (amortized cost of |
$ |
879,989 |
|
|
$ |
554,624 |
|
Short-term investments, at amortized cost, which approximates fair value |
|
9,997 |
|
|
|
8,824 |
|
Total investments |
|
889,986 |
|
|
|
563,448 |
|
|
|
|
|
||||
Cash and cash equivalents |
|
97,476 |
|
|
|
118,070 |
|
Restricted cash and cash equivalents |
|
124,582 |
|
|
|
1,698 |
|
Accrued investment income |
|
7,520 |
|
|
|
4,660 |
|
Premium balances receivable |
|
63,672 |
|
|
|
38,817 |
|
Reinsurance recoverable |
|
255,072 |
|
|
|
139,389 |
|
Prepaid reinsurance premiums |
|
152,567 |
|
|
|
116,732 |
|
Deferred policy acquisition costs |
|
27,625 |
|
|
|
19,407 |
|
Property and equipment, net |
|
6,845 |
|
|
|
7,601 |
|
Income taxes receivable |
|
586 |
|
|
|
1,107 |
|
Deferred tax assets, net |
|
20,340 |
|
|
|
14,229 |
|
Other assets |
|
7,971 |
|
|
|
2,701 |
|
Total assets |
$ |
1,654,242 |
|
|
$ |
1,027,859 |
|
|
|
|
|
||||
Liabilities |
|
|
|
||||
Reserve for losses and loss adjustment expenses |
$ |
756,859 |
|
|
$ |
431,186 |
|
Unearned premiums |
|
446,850 |
|
|
|
344,704 |
|
Reinsurance balances payable |
|
51,856 |
|
|
|
40,440 |
|
Income taxes payable |
|
1,571 |
|
|
|
42 |
|
Accrued expenses |
|
18,010 |
|
|
|
14,900 |
|
Other liabilities |
|
8,654 |
|
|
|
4,510 |
|
Total liabilities |
|
1,283,800 |
|
|
|
835,782 |
|
|
|
|
|
||||
Commitments and contingencies (Note 13) |
|
|
|
||||
|
|
|
|
||||
Mezzanine equity |
|
|
|
||||
Performance stock units |
|
265 |
|
|
|
— |
|
|
|
|
|
||||
Stockholders' equity |
|
|
|
||||
Common stock |
|
327 |
|
|
|
240 |
|
( |
|
|
|
||||
Additional paid-in capital |
|
318,095 |
|
|
|
178,543 |
|
Accumulated other comprehensive loss |
|
(11,154 |
) |
|
|
(11,372 |
) |
Retained earnings |
|
62,909 |
|
|
|
24,666 |
|
Total stockholders' equity |
|
370,177 |
|
|
|
192,077 |
|
Total mezzanine equity and stockholders' equity |
|
370,442 |
|
|
|
192,077 |
|
|
|
|
|
||||
Total liabilities, mezzanine equity and stockholders' equity |
$ |
1,654,242 |
|
|
$ |
1,027,859 |
|
Gross Written Premiums
The following tables present gross written premiums by underwriting division for the three and twelve months ended December 31, 2024 and 2023:
|
Three Months Ended December 31, |
|||||||||||||||||||
|
|
2024 |
|
|
% of Total |
|
|
2023 |
|
|
% of Total |
|
$ Change |
|
% Change |
|||||
|
($ in thousands, except percentages) |
|||||||||||||||||||
Casualty |
$ |
105,872 |
|
|
57.3 |
% |
|
$ |
73,993 |
|
|
50.6 |
% |
|
$ |
31,879 |
|
|
43.1 |
% |
Professional Liability |
|
46,010 |
|
24.9 |
% |
|
|
43,195 |
|
29.5 |
% |
|
|
2,815 |
|
6.5 |
% |
|||
Healthcare Liability |
|
31,699 |
|
|
17.2 |
% |
|
|
29,133 |
|
|
19.9 |
% |
|
|
2,566 |
|
|
8.8 |
% |
Baleen Specialty |
|
1,188 |
|
|
0.6 |
% |
|
|
— |
|
|
— |
% |
|
|
1,188 |
|
|
NM |
|
Gross written premiums |
$ |
184,769 |
|
|
100.0 |
% |
|
$ |
146,321 |
|
|
100.0 |
% |
|
$ |
38,448 |
|
|
26.3 |
% |
|
Twelve Months Ended December 31, |
|||||||||||||||||||
|
|
2024 |
|
|
% of Total |
|
|
2023 |
|
|
% of Total |
|
$ Change |
|
% Change |
|||||
|
($ in thousands, except percentages) |
|||||||||||||||||||
Casualty |
$ |
431,817 |
|
|
62.1 |
% |
|
$ |
277,455 |
|
|
54.7 |
% |
|
$ |
154,362 |
|
|
55.6 |
% |
Professional Liability |
|
160,651 |
|
23.1 |
% |
|
|
145,251 |
|
28.6 |
% |
|
|
15,400 |
|
10.6 |
% |
|||
Healthcare Liability |
|
101,619 |
|
|
14.6 |
% |
|
|
84,982 |
|
|
16.7 |
% |
|
|
16,637 |
|
|
19.6 |
% |
Baleen Specialty |
|
1,630 |
|
|
0.2 |
% |
|
|
— |
|
|
— |
% |
|
|
1,630 |
|
|
NM |
|
Gross written premiums |
$ |
695,717 |
|
|
100.0 |
% |
|
$ |
507,688 |
|
|
100.0 |
% |
|
$ |
188,029 |
|
|
37.0 |
% |
Loss Ratio
The following tables summarize current and prior accident year loss ratios for the three and twelve months ended December 31, 2024 and 2023:
|
Three Months Ended December 31, |
||||||||||||
|
2024 |
|
2023 |
||||||||||
|
Net Losses and Loss Adjustment Expenses |
|
% of Net Earned Premiums |
|
Net Losses and Loss Adjustment Expenses |
|
% of Net Earned Premiums |
||||||
|
($ in thousands, except percentages) |
||||||||||||
Current accident year |
$ |
66,937 |
|
|
62.6 |
% |
|
$ |
53,254 |
|
|
70.0 |
% |
Prior accident year reserve development |
|
— |
|
— |
% |
|
|
(636 |
) |
|
(0.8 |
)% |
|
Total |
$ |
66,937 |
|
|
62.6 |
% |
|
$ |
52,618 |
|
|
69.2 |
% |
|
Twelve Months Ended December 31, |
||||||||||||
|
2024 |
|
2023 |
||||||||||
|
Net Losses and Loss Adjustment Expenses |
|
% of Net Earned Premiums |
|
Net Losses and Loss Adjustment Expenses |
|
% of Net Earned Premiums |
||||||
|
($ in thousands, except percentages) |
||||||||||||
Current accident year |
$ |
248,099 |
|
|
64.4 |
% |
|
$ |
166,282 |
|
|
63.0 |
% |
Prior accident year reserve development |
|
— |
|
— |
% |
|
|
— |
|
— |
% |
||
Total |
$ |
248,099 |
|
|
64.4 |
% |
|
$ |
166,282 |
|
|
63.0 |
% |
Expense Ratio
The following tables summarize the components of our expense ratio for the three and twelve months ended December 31, 2024 and 2023:
|
Three Months Ended December 31, |
||||||||||||
|
2024 |
|
2023 |
||||||||||
|
Expenses |
|
% of Net Earned Premiums |
|
Expenses |
|
% of Net Earned Premiums |
||||||
|
($ in thousands, except percentages) |
||||||||||||
Net acquisition costs |
$ |
9,130 |
|
|
8.5 |
% |
|
$ |
5,787 |
|
|
7.6 |
% |
Operating expenses |
|
23,352 |
|
|
21.9 |
% |
|
|
18,001 |
|
|
23.7 |
% |
Less: Other insurance-related income |
|
(274 |
) |
|
(0.3 |
)% |
|
|
(31 |
) |
|
— |
% |
Total expense ratio |
$ |
32,208 |
|
|
30.1 |
% |
|
$ |
23,757 |
|
|
31.3 |
% |
|
Twelve Months Ended December 31, |
||||||||||||
|
2024 |
|
2023 |
||||||||||
|
Expenses |
|
% of Net Earned Premiums |
|
Expenses |
|
% of Net Earned Premiums |
||||||
|
($ in thousands, except percentages) |
||||||||||||
Net acquisition costs |
$ |
32,397 |
|
|
8.4 |
% |
|
$ |
20,935 |
|
|
7.9 |
% |
Operating expenses |
|
89,112 |
|
|
23.1 |
% |
|
|
63,456 |
|
|
24.0 |
% |
Less: Other insurance-related income |
|
(444 |
) |
|
(0.1 |
)% |
|
|
(125 |
) |
|
— |
% |
Total expense ratio |
$ |
121,065 |
|
|
31.4 |
% |
$ |
84,266 |
|
|
31.9 |
% |
Net Investment Income
The following table summarizes the sources of net investment income for the three and twelve months ended December 31, 2024 and 2023:
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
($ in thousands) |
||||||||||||||
|
$ |
3,198 |
|
|
$ |
2,511 |
|
|
$ |
14,514 |
|
|
$ |
4,673 |
|
State and municipal |
|
591 |
|
|
|
387 |
|
|
|
1,832 |
|
|
|
1,550 |
|
Commercial mortgage-backed securities |
|
981 |
|
|
|
378 |
|
|
|
2,584 |
|
|
|
1,381 |
|
Residential mortgage-backed securities |
|
2,399 |
|
|
|
244 |
|
|
|
6,517 |
|
|
|
962 |
|
Asset-backed securities |
|
1,283 |
|
|
|
1,171 |
|
|
|
3,043 |
|
|
|
3,708 |
|
Corporate |
|
2,154 |
|
|
|
934 |
|
|
|
5,768 |
|
|
|
3,448 |
|
Short-term investments |
|
130 |
|
|
|
126 |
|
|
|
480 |
|
|
|
943 |
|
Cash and cash equivalents |
|
1,700 |
|
|
|
1,179 |
|
|
|
6,193 |
|
|
|
3,190 |
|
Gross investment income |
|
12,436 |
|
|
|
6,930 |
|
|
|
40,931 |
|
|
|
19,855 |
|
Investment expenses |
|
(243 |
) |
|
|
(148 |
) |
|
|
(810 |
) |
|
|
(484 |
) |
Net investment income |
$ |
12,193 |
|
|
$ |
6,782 |
|
|
$ |
40,121 |
|
|
$ |
19,371 |
|
Reconciliation of Non-GAAP Financial Measures
This earnings release contains certain financial measures that are not presented in accordance with generally accepted accounting principles in
- Adjusted net income is defined as net income excluding the impact of net realized investment losses, non-operating expenses, foreign exchange losses (gains), and certain strategic initiatives. Adjusted net income excludes the impact of certain items that may not be indicative of underlying business trends, operating results, or future outlook, net of tax impact. We calculate the tax impact only on adjustments that would be included in calculating our income tax expense using the estimated tax rate at which we received a deduction for these adjustments.
- Adjusted return on equity is defined as adjusted net income as a percentage of average beginning and ending mezzanine equity and stockholders’ equity.
- Diluted adjusted earnings per share is defined as adjusted net income divided by the weighted average common shares outstanding for the period, reflecting the dilution that may occur if equity based awards are converted into common stock equivalents as calculated using the treasury stock method.
You should not rely on these non-GAAP financial measures as a substitute for any
Adjusted net income
Adjusted net income for the three and twelve months ended December 31, 2024 and 2023 reconciles to net income as follows:
|
Three Months Ended December 31, |
||||||||||||||
|
2024 |
|
2023 |
||||||||||||
|
Before income taxes |
|
After income taxes |
|
Before income taxes |
|
After income taxes |
||||||||
|
($ in thousands) |
||||||||||||||
Income as reported |
$ |
18,249 |
|
|
$ |
13,607 |
|
|
$ |
5,810 |
|
|
$ |
4,783 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Non-operating expenses |
|
622 |
|
|
622 |
|
|
|
630 |
|
|
|
630 |
|
|
Foreign exchange losses (gains) |
|
1 |
|
|
|
1 |
|
|
|
(41 |
) |
|
|
(41 |
) |
Strategic initiatives(1) |
|
— |
|
|
|
— |
|
|
|
706 |
|
|
|
706 |
|
Tax impact |
|
— |
|
|
|
(131 |
) |
|
|
— |
|
|
|
(285 |
) |
Adjusted net income |
$ |
18,872 |
|
|
$ |
14,099 |
|
|
$ |
7,105 |
|
|
$ |
5,793 |
|
|
Twelve Months Ended December 31, |
||||||||||||||
|
2024 |
|
2023 |
||||||||||||
|
Before income taxes |
|
After income taxes |
|
Before income taxes |
|
After income taxes |
||||||||
|
($ in thousands) |
||||||||||||||
Income as reported |
$ |
50,535 |
|
|
$ |
38,243 |
|
|
$ |
32,115 |
|
|
$ |
25,047 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Net realized investment losses |
|
16 |
|
|
16 |
|
|
|
— |
|
|
|
— |
|
|
Non-operating expenses |
|
2,807 |
|
|
|
2,807 |
|
|
|
630 |
|
|
|
630 |
|
Foreign exchange losses (gains) |
|
68 |
|
|
|
68 |
|
|
|
(20 |
) |
|
|
(20 |
) |
Strategic initiatives(1) |
|
2,733 |
|
|
|
2,733 |
|
|
|
806 |
|
|
|
806 |
|
Tax impact |
|
— |
|
|
|
(1,181 |
) |
|
|
— |
|
|
|
(311 |
) |
Adjusted net income |
$ |
56,159 |
|
|
$ |
42,686 |
|
|
$ |
33,531 |
|
|
$ |
26,152 |
|
____________________ |
||
(1) |
|
Strategic initiatives for the three months and years ended December 31, 2024 and 2023 represents costs incurred to set up our Baleen Specialty division, which is recorded in operating expenses within the Consolidated Statements of Income and Comprehensive Income. The costs incurred primarily represent expenses to implement the new platform and processes supporting the Baleen Specialty division. See “Business— Our Business” |
Adjusted return on equity
Adjusted return on equity for the three and twelve months ended December 31, 2024 and 2023 reconciles to return on equity as follows:
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
($ in thousands, except percentages) |
||||||||||||||
Numerator: Adjusted net income(1) |
$ |
56,395 |
|
|
$ |
23,172 |
|
|
$ |
42,686 |
|
|
$ |
26,152 |
|
Denominator: Average mezzanine equity and stockholders' equity |
|
367,467 |
|
|
|
173,251 |
|
|
|
281,259 |
|
|
|
137,726 |
|
Adjusted return on equity |
|
15.3 |
% |
|
|
13.4 |
% |
|
|
15.2 |
% |
|
|
19.0 |
% |
____________________ |
||
(1) |
|
For the three months ended December 31, 2024 and 2023, net income and adjusted net income are annualized to arrive at return on equity and adjusted return on equity. |
Diluted adjusted earnings per share
Diluted adjusted earnings per share for the three and twelve months ended December 31, 2024 and 2023 reconciles to diluted earnings per share as follows:
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
($ in thousands, except share and per share data) |
||||||||||||||
Numerator: Adjusted net income |
$ |
14,099 |
|
|
$ |
5,793 |
|
|
$ |
42,686 |
|
|
$ |
26,152 |
|
Denominator: Diluted weighted average shares outstanding |
|
33,571,535 |
|
|
|
24,000,000 |
|
|
|
29,677,196 |
|
|
|
24,000,000 |
|
Diluted adjusted earnings per share |
$ |
0.42 |
|
|
$ |
0.24 |
|
|
$ |
1.44 |
|
|
$ |
1.09 |
|
About Bowhead Specialty Holdings Inc.
Bowhead Specialty is a specialty lines insurance group providing casualty, professional liability and healthcare liability insurance products. The team is composed of highly experienced and respected industry veterans with decades of individual, successful underwriting and management experience. We provide “craft” underwriting solutions, which require deep underwriting and claims expertise in order to produce attractive financial results. In May 2024, we supplemented our “craft” solution with our “flow” underwriting operation, which is a streamlined, tech-enabled low touch form of underwriting, focused on small, niche and hard-to-place risks. Our policies are primarily written on a non-admitted, or excess and surplus lines (“E&S”) basis, which is free of rate and policy form restrictions, and provides the flexibility to rapidly adjust to emerging market opportunities.
We pride ourselves on the quality and experience of our people, who are committed to exceeding our partners’ expectations through excellent service and expertise. Our collaborative culture spans all functions of our business, which allows us to provide a consistent, positive experience for all of our partners.
Conference Call
The Company will host a conference call to discuss its results today, Tuesday, February 25, 2025, beginning at 8:30 a.m. Eastern Time. Interested parties may access the conference call through a live webcast, which can be accessed via this link or by visiting the Company’s Investor Relations website. A dial-in option for listen-only participants will be available after registering for the call. Please join the live webcast or dial in at least 10 minutes before the start of the call.
A replay of the event webcast will be available on the company’s Investor Relations website for one year following the call.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "seeks," "future," "outlook," "prospects" "will," "would," "should," "could," "may," "can have" or similar words. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. These risks include those described in the Company’s filings made with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this press release and the Company does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225372984/en/
Investor Relations Contact:
Shirley Yap, Head of Investor Relations
investorrelations@bowheadspecialty.com
Source: Bowhead Specialty Holdings Inc.
FAQ
What were Bowhead Specialty Holdings' Q4 2024 financial results?
How did Bowhead Specialty Holdings perform in the full year 2024?
What was the return on equity for Bowhead Specialty Holdings in Q4 2024?
What was the increase in premiums for Bowhead Specialty Holdings' Casualty division?
What is Baleen and how did it perform in Q4 2024?